GIA
HUMA icon

Gladstone Institutional Advisory’s Humacyte HUMA Stock Holding History

Gladstone Institutional Advisory’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,098
Closed -$25.5K – 683
2022
Q4 		$25.5K Sell
12,098
-75,325
-86% -$229K ﹤0.01% 634
2022
Q3 		$285K Sell
87,423
-50,097
-36% -$192K 0.02% 508
2022
Q2 		$441K Sell
137,520
-7,347
-5% -$40.8K 0.03% 434
2022
Q1 		$1.02M Sell
144,867
-101,850
-41% -$593K 0.07% 288
2021
Q4 		$1.79M Buy
+246,717
New +$2.44M 0.14% 198

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
IW
Imprint Wealth Mount Pleasant, South Carolina $21.9M AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Gladstone Institutional Advisory's HUMA Position: Q1 2023 in Review

Gladstone Institutional Advisory sold out of Humacyte (HUMA) in Q1 2023, closing a stake of 12,098 shares — an estimated $25.5K sold.

Gladstone Institutional Advisory first reported a position in HUMA in Q4 2021 and held it in 5 quarters. The position peaked at $1.79M in Q4 2021. 69 funds tracked by Wall St. Rank hold HUMA as of Q1 2023.

  • Gladstone Institutional Advisory reported no remaining Humacyte position as of Q1 2023 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 12,098 Humacyte shares in Q1 2023, an estimated $25.5K.
  • Gladstone Institutional Advisory first reported a position in Humacyte in Q4 2021 and held it in 5 quarters.
  • Gladstone Institutional Advisory's Humacyte position peaked at $1.79M in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Humacyte as of Q1 2023.

Based on Gladstone Institutional Advisory's 13F filing for Q1 2023, filed 12 May 2023.